ストックスクリーナーアプリを入手
5.51
0.72%
-0.04
アフターアワーズ：
5.40
-0.11
-2.00%
前日終値:
$5.55
開ける：
$5.7
24時間の取引高:
44,742
Relative Volume:
0.30
時価総額：
$34.41M
収益：
$4.71M
当期純損益:
$-90.32M
株価収益率:
-0.6331
EPS:
-8.7032
ネットキャッシュフロー:
$-85.19M
1週間 パフォーマンス:
+5.15%
1か月 パフォーマンス:
-26.24%
6か月 パフォーマンス:
-20.83%
1年 パフォーマンス:
-41.13%
1日の値動き範囲:
$5.47
$5.765
1週間の範囲:
$5.21
$6.30
52週間の値動き範囲:
$3.98
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
名前
Aligos Therapeutics Inc
セクター
電話
(800) 466-6059
住所
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.51 | 34.66M | 4.71M | -90.32M | -85.19M | -8.7032 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-19 | 再開されました | Jefferies | Buy |
| 2025-08-18 | 再開されました | H.C. Wainwright | Buy |
| 2024-08-19 | 開始されました | H.C. Wainwright | Buy |
| 2023-01-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-01-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-09 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 再開されました | Piper Sandler | Overweight |
| 2020-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 開始されました | JP Morgan | Overweight |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Aligos Therapeutics Inc (ALGS) 最新ニュース
Aligos Therapeutics Amends Long-Term Headquarters Lease Agreement - TipRanks
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
Technical Reactions to ALGS Trends in Macro Strategies - Stock Traders Daily
Avoiding Lag: Real-Time Signals in (ALGS) Movement - Stock Traders Daily
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Stocktwits
Aligos Therapeutics at Cantor Fitzgerald conference: hbv pipeline in focus By Investing.com - Investing.com India
Liquidity Mapping Around (ALGS) Price Events - Stock Traders Daily
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference - Investing News Network
Why is Aligos Therapeutics stock rallying 7% today? - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Why is Aligos Therapeutics stock rallying 7% today? By Investing.com - Investing.com India
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates - Yahoo Finance
Stock Market News - Investing.com South Africa
Aligos Therapeutics (ALGS) Stock Forum and Discussion - Moomoo
Aligos Therapeutics and Katholieke Universiteit Leuven patent new Mpro inhibitors - BioWorld News
Aligos Therapeutics Inc (ALGS) Peer Comparison – Compare with Others - Value Research
Aligos Hepatitis B Trial Completion: What Phase 1 Liver Data Mean for ALGS Investors - TipRanks
Aligos Therapeutics Company Profile & Introduction - Moomoo
Aligos Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Why (ALGS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Industry Analysts Just Upgraded Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts By 68% - Moomoo
Aligos Therapeutics (ALGS) Slips 1.55% to $6.67 as Biotech Stock Holds Above Key SupportSector Leader Stocks - vinanet.vn
Aligos Therapeutics, Inc. (ALGS) Stock Price, News, Quote & History - Yahoo Finance
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - Investing News Network
Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China - TradingView
Aligos begins phase 1 trial of hepatitis B treatment in China - Investing.com South Africa
Aligos Begins Testing a Chronic Hepatitis B Candidate in China - Stock Titan
Industry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts - simplywall.st
H.C. Wainwright reiterates Aligos stock rating on HBV progress By Investing.com - Investing.com UK
H.C. Wainwright reiterates Aligos stock rating on HBV progress - Investing.com
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Lake Street Keeps Their Buy Rating on Aligos Therapeutics (ALGS) - The Globe and Mail
Aligos Therapeutics Inc (NASDAQ:ALGS) - intelligentinvestor.com.au
ALGS Q2 2026 Earnings: Narrowed Loss Beats Estimates by 87% as Stock Advances 1.45Healthcare Earnings Report - Vinanet
Cantor Fitzgerald Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Aligos earnings beat by $1.01, revenue topped estimates - Investing.com Canada
Form 8K Aligos Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Form 8K Aligos Therapeutics Inc For: 6 August - Investing.com India
Aligos Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aligos Therapeutics Reports $1.5 Million Q2 Net Loss and Pipeline Progress | ALGS Stock News - Quiver Quantitative
Aligos Therapeutics 2Q 2026: Revenue $—, Net income $(1.50)M, EPS $(0.14) — 10-Q Summary - TradingView
ALGS: $27.8M licensing revenue drove a smaller Q2 loss; cash runway into Q4 2026, funding needed - TradingView
Aligos Therapeutics (Nasdaq: ALGS) logs Q2 loss but lands $27.8M HBV license revenue - Stock Titan
Aligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash - TradingView
ALGS: Pipeline advances and licensing deals strengthen financials and outlook for HBV therapies - TradingView
ALIGOS THERAPEUTICS Q2 NET INCOME USD -1.504 MILLION - Moomoo
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results - Yahoo Finance
ALGS Q2'26 Earnings: EPS estimate is (1.09) USD - TradingView
Aligos Therapeutics, Inc. expected to post a loss of $1.07 a shareEarnings Preview - TradingView
Aligos Therapeutics (ALGS) Rises 0.87% to $4.64, Holds Above SupportRSI Oversold Picks - vinanet.vn
Aligos Therapeutics Inc (ALGS) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):